Bristol Myers’ Breyanzi Expands Indications to Include Follicular Lymphoma

1. Bristol Myers Squibb's CAR-T therapy, Breyanzi (lisocabtagene maraleucel), has recently received approval from the U.S. Food and Drug Administration (FDA) for the treatment of follicular lymphoma.
2. Follicular lymphoma is a type of slow-growing non-Hodgkin lymphoma, which is a cancer of the lymphatic system.
3. Breyanzi is a chimeric antigen receptor (CAR) T-cell therapy, a type of immunotherapy that uses genetically modified T-cells to target and destroy cancer cells.
4. This approval marks the third indication for Breyanzi, which was previously approved for the treatment of large B-cell lymphoma and mantle cell lymphoma.
5. The approval was based on the results of a clinical trial, which demonstrated significant efficacy and manageable safety in patients with follicular lymphoma.
6. Breyanzi is part of a new generation of cancer treatments that harness the power of the immune system to fight cancer.
7. Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines to help patients prevail over serious diseases.